Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in Interest ReceivablesChange in Net LoansChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

iBio (IBIO) Change in Accured Expenses (2016 - 2025)

iBio (IBIO) has disclosed Change in Accured Expenses for 16 consecutive years, with $567000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 6987.5% to $567000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $67000.0, a 103.75% increase, with the full-year FY2025 number at -$758000.0, up 56.08% from a year prior.
  • Change in Accured Expenses was $567000.0 for Q4 2025 at iBio, up from -$686000.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $2.4 million in Q4 2022 to a low of -$1.3 million in Q1 2023.
  • A 5-year average of $40050.0 and a median of $52000.0 in 2022 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: crashed 1407.29% in 2023, then surged 6987.5% in 2025.
  • iBio's Change in Accured Expenses stood at $791000.0 in 2021, then skyrocketed by 204.05% to $2.4 million in 2022, then crashed by 100.29% to -$7000.0 in 2023, then soared by 214.29% to $8000.0 in 2024, then soared by 6987.5% to $567000.0 in 2025.
  • Per Business Quant, the three most recent readings for IBIO's Change in Accured Expenses are $567000.0 (Q4 2025), -$686000.0 (Q3 2025), and -$54000.0 (Q2 2025).